A Phase 3 interventional study of Mavacamten and Placebo in Cardiomyopathy, Hypertrophic, sponsored by Bristol-Myers Squibb. Active, not recruiting at 47 sites in 9 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-12-19.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic — 3 open to participants now, 7 under way, 1 of them phase 3. MYK-461 · Cardiomyopathy, Hypertrophic.
Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, this one is the 17th largest by enrollment, is one of 2 that started in 2024, is one of 6 in phase 3, and was the 16th registered.
363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →3 of the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic are open now, in 2 countries. Recruiting first, the newest first:
University of Manchester · Sites in United Kingdom
Ages 18+
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University
Ages 18+
By country, each count listing its studies:
MYK-461: first FDA approval 2022 (CAMZYOS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 7 · Phase 4 4
First in 2014; this study’s year is marked. 2 started in 2024.
This study's enrollment of 44 is below the median of 60 across 180 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 75 across the 21 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 7 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb: 9 open now, 14 under way, 1 of them phase 3. Of 17 finished, 8 (47%) have results posted.
Among the 31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, this one is the 11th largest by enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2024, is one of 5 in phase 3, reaches primary completion later than 2 of the 13 other live ones, and was the 19th registered.
Bristol-Myers Squibb’s Cardiomyopathy, Hypertrophic studies by the year they started, since 2014.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, from their registry updates:
Among Bristol-Myers Squibb’s 31 in Cardiomyopathy, Hypertrophic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined Inclusion/Exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this arm will receive mavacamten (1 mg to 15 mg) from day 1 to end of treatment at week 200.
Drug: Mavacamten
Participants assigned to this arm will receive mavacamten (1 mg to 15 mg) from week 28 to end of treatment at week 200.
Drug: Placebo
Specified dose on specified days
Also known as: BMS-986427
Specified dose on specified days
Change from baseline in Valsalva left ventricular outflow tract (LVOT) (VLVOT) gradient
Time frame: At Week 28
Change from baseline in resting LVOT gradient
Time frame: At Week 28
Change from baseline in post-exercise peak LVOT gradient
Time frame: At Week 28
Change from baseline in maximal wall thickness
Time frame: At Week 28
Change from baseline in ratio between early mitral inflow velocity and mitral annular early diastolic velocity (E/e')
Time frame: At Week 28
Proportion of participants achieving an increase from baseline to Week 28 in peak oxygen uptake test (pVO2)
Time frame: From baseline up to Week 28
Proportion of participants achieving a reduction from baseline to Week 28 in maximal LVOT gradient to < 30 mmHg
Time frame: From baseline up to Week 28
Proportion of participants with at least 1 class improvement in New York Heart Association (NYHA) class from baseline to Week 28
Time frame: From baseline up to Week 28
Proportion of participants with at least 1 grade improvement in mitral regurgitation at Week 28
Time frame: From baseline up to Week 28
Number of participants with treatment-emergent adverse events (TEAEs)
Time frame: Up to Week 218
Number of participants with treatment-emergent serious adverse events (TESAEs)
Time frame: Up to Week 218
Change from baseline in electrocardiogram (ECG) (QT interval)
Time frame: At Week 28
Number of participants with left ventricular ejection fraction (LVEF) ≤ 30%
Time frame: Up to Week 200
Number of participants with LVEF < 50%
Time frame: Up to Week 200
Trough observed plasma concentration (Ctrough)
Time frame: Up to Week 200
Post-dose plasma concentration of mavacamten
Time frame: Up to Week 200
Maximum observed concentration (Cmax)
Time frame: Up to Week 200
Area under the concentration-time curve (AUC)
Time frame: Up to Week 200
Proportion of participants who evaluate taste and swallowability as neutral or better using taste and swallowability scales
Time frame: At Day 1 and Week 11
Change from baseline in the Hypertrophic Cardiomyopathy Symptom Questionnaire - Shortness of Breath (HCMSQ SoB) domain
Time frame: At Week 28
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · www.bms.com
Ran from Apr 2024 to primary completion in Nov 2025, 19 months.
Of 15 phase 3 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 19 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MYK-461
Cardiomyopathy, Hypertrophic →